| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.094 | 0.04 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.04 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |